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Abstract
Background Non-adherence to medication is a challenging problem in daily clinical practice.
Objective To assess reasons for non-adherence in patients with chronic immune-mediated inﬂammatory diseases
(IMIDs) in a direct comparison including evaluation of treatment necessity and concerns.
Methods ALIGN was a non-interventional, multicountry, multicentre, self-administered, cross-sectional, epidemiologic
survey study. Here, we investigate the German, Austrian and Swiss (DACH) cohort. Six hundred thirty-one patients with
different IMIDs (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease and
ulcerative colitis) under systemic therapies were evaluated concerning adherence, beliefs of necessity and concerns
towards treatment in patients with IMIDs.
Results The DACH cohort had signiﬁcantly different levels of adherence depending on the IMID (P < 0.05) and the type
of therapy (P < 0.05). Based on the signiﬁcant inﬂuence of concerns on treatment adherence (P < 0.05) and the high
belief of treatment necessity, patients could be classiﬁed in four attitudinal segments, which were unequally distributed
throughout various IMIDs. High concerns had a signiﬁcant inﬂuence on non-adherence, whereas necessity did not. Older
age, female sex, TNFi mono-, conventional combination and TNFi combination therapy are positively associated with
adherence.
Conclusions In the DACH region, patients are less concerned about medication and believe in the necessity of treat-
ment. Therefore, we suggest adapting the communication in the various patient groups.
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Introduction
Immune-mediated inflammatory diseases (IMIDs) describe a
group of conditions characterized by chronic inflammation,
including rheumatoid arthritis (RA), ankylosing spondylitis
(AS), psoriatic arthritis (PSA), ulcerative colitis (UC), Crohn’s
disease (CD) and psoriasis (PSO).1–3 IMIDs can be treated effec-
tively but often need lifelong medication, which necessitates
long-term adherence. Adherence is defined by the WHO as the
extent to which a person’s behaviour corresponds with the rec-
ommendations from his or her healthcare professional (HCP).
Non-adherence to medication is a challenging problem in daily
clinical practice, resulting in increased healthcare costs, reduced
quality of life, poor treatment outcomes, higher risk and prolon-
gation of hospitalization, inappropriate therapeutic decisions
due to underestimation of treatment efficacy and decreased
patient satisfaction.4 In chronic diseases, up to 50% of the medi-
cation is not taken as prescribed1,5–7 and adherence ranges from
7% to 80% in RA, PSO, UC or CD.2,4,8,9 Non-adherence can be
driven by intentional and unintentional motivations including
relationship of the HCP with the patient, lower treatment neces-
sity, treatment concerns and depression.2
ALIGN was a multicountry, cross-sectional study to deter-
mine patient specific and general beliefs towards medication and
treatment compliance to selected systemic therapies, as well as
illness perceptions in IMIDs.
The primary objective of the ALIGN study was to assess
treatment necessity and concerns in patients with chronic
IMIDs. Secondary objectives were to define patients’ beliefs and
adherence about systemic medications and distribution of
adherence among different IMIDs. Herein, the data for the
DACH region (Deutschland = Germany, Austria, Confoederatio
Helvetica = Switzerland) from the global ALIGN data were
analysed.10
Hence, identifying the reasons for non-adherence in patients
with IMIDs is of paramount importance to generate tools and
educational programs. Additionally, a practical tool with com-
munication strategies for different patient types was developed.
Materials and methods
The ALIGN study was conducted between June 2012 and Octo-
ber 2013 and the DACH cohort included 631 patients from 7328
patients worldwide.10 Participants were ≥18 years old, attended
routine outpatient visits for different IMIDs diagnosed by a
rheumatologist (RA, PSA, AS), dermatologist (PSO, PSA), or
gastroenterologist (CD, UC), and were being treated with sys-
temic disease-modifying antirheumatic drugs (DMARDs), glu-
cocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs;
only AS) and/or tumour necrosis factor inhibitors (TNFi). Writ-
ten informed consent was obtained before inclusion in the study.
The study protocol was conducted in accordance with the Decla-
ration of Helsinki 2013, local regulatory laws and local ethics
committee of each participating country.Trial registration: ACTRN12612000977875. Funded by AbbVie Inc.
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Data were collected at a single visit during a routine check-up
where each patient had to complete four validated question-
naires in a validated language version: Beliefs about Medicines
Questionnaire,11 scoring beliefs about treatment overuse and
harm (BMQ-General), and necessity and concerns (BMQ-
Specific) using a 5-point Likert scale (1 = strongly disagree;
2 = disagree; 3 = uncertain; 4 = agree; 5 = strongly agree); the
4-item Morisky Medication Adherence Scale (MMAS-4),12–14
consisting of four (yes = 0; no = 1) questions, with high
adherence defined as a score of 4; the Brief Illness Perception
Questionnaire (BIPQ),15 measuring perception of illness with
eight questions using an 11-point scale; and the Patient Health
Questionnaire-2 (PHQ-2),16 which consists of two questions
measuring depressive symptoms; and a visual analogue scale
(VAS),17 measured from 0% to 100% to assess the medication
taken during the 3 months before the study visit. After comple-
tion, all patient questionnaires were placed into confidential
sealed envelopes. The investigators provided the data on patient
demographics, social, economic, and educational background,
IMID-related data, previous and current treatment and response
to therapy.
Treatments included TNFi monotherapy (‘TNFi mono’),
TNFi combined with conventional therapies (‘TNFi combo’) or
conventional therapies only (‘conventional only’; Table 1). The
BMQ-General (Overuse and Harm) were evaluated in three
groups: TNFi mono, TNFi combo and conventional only. The
BMQ-Specific (Necessity and Concerns) and MMAS-4 adherence
rates were evaluated in four groups: TNFi mono; conventional
only; and TNFi combo, which was split into a TNFi component
(‘TNFi combo-TNFi rating’) as well as the conventional therapy
component (‘TNFi combo-conventional rating’).
Multiple regression analyses were performed to estimate fac-
tors affecting BMQ-Specific (linear regression) and high medica-
tion adherence (logistic regression). Covariates in these analyses
Table 1 Demographics, prior and current disease severity, current therapies, and duration of disease and symptoms of the ALIGN-
DACH population
Rheumatology
n = 209
(33.1%)
Dermatology
n = 205
(32.5%)
Gastroenterology
n = 217
(34.4%)
RA AS PSA PSO CD UC
(n = 100) (n = 44) (n = 65) (n = 205) (n = 145) (n = 72)
Female patients, % 75 34.1 43.1 60.7 43.1 33.7
Age, 55.2 43.6 48.8 48.1 35.8 43.1
Mean (range), years (23–78) (24–79) (23–76) (20–83) (18–74) (19–81)
Disease duration, 9.1 7.4 9.4 18 9.3 9.6
Mean (range), years (0.2–37.1) (0.1–32.7) (0.3–51.6) (0.1–38.9) (0.8–42.4) (0.12–72.6)
Prior initial treatment disease severity, % (number) of patients
Mild 3 (3) 4.5 (2) 3.1 (2) 6.3 (13) 0.7 (1) 1.4 (1)
Mild to moderate 8 (8) 13.6 (6) 4.6 (3) 3.4 (7) 6.9 (10) 11.1 (8)
Moderate 35 (35) 27.3 (12) 21.5 (14) 9.3 (19) 18.6 (27) 29.2 (21)
Moderate to severe 35 (35) 34.1 (15) 47.7 (31) 41 (81) 49.7 (72) 30.6 (22)
Severe 19 (19) 20.5 (9) 23.1 (15) 40 (82) 24.1 (35) 27.8 (29)
Current disease severity, % (number) of patients
Mild 44 (44) 52.3 (23) 60 (39) 63.4 (130) 57.2 (83) 4.,6 (35)
Mild to moderate 26 (26) 20.5 (9) 24.6 (16) 18.5 (38) 22.1 (32) 18.1 (13)
Moderate 21 (21) 15.9 (7) 6.2 (4) 9.3 (19) 15.2 (22) 18.1 (13)
Moderate to severe 9 (9) 6.8 (3) 6.2 (4) 7.3 (15) 4.1 (6) 11.1 (8)
Severe 0 (0) 4.5 (2) 3.1 (2) 1.5 (3) 1.4 (2) 4.2 (3)
Current IMID-related drugs, % (number) of patients
TNFi monotherapy 15 (15) 54.5 (24) 53.8 (35) 49.8 (102) 44.8 (65) 15.3 (11)
TNFI combination therapy 45 (45) 31.8 (14) 26.2 (17) 1 (2) 28.3 (41) 33.3 (24)
Conventional systemic therapy 40 (40) 13.6 (6) 20 (13) 49.3 (101) 26.9 (39) 51.4 (37)
Duration of disease mean years (deviation)
Overall 10 (9.1) 8.5 (7.4) 9,4 (10.5) 18 (14.1) 9.3 (8.7) 9.6 (9.4)
Duration of symptoms prior to diagnosis, number (%) of patients
<1 year 60 (60) 12 (27.3) 21 (32.3) 111 (54.4) 73 (50.7) 52 (72.2)
1–3 years 19 (19) 11 (25) 18 (27.7) 28 (13.7) 45 (31.3) 10 (13.9)
>3 years 21 (21) 21 (47.7) 26 (40) 65 (31.9) 26 (18.1) 10 (13.9)
DACH, Deutschland (Germany), Austria, Confoederatio Helvetica (Switzerland); TNFi, tumour necrosis factor inhibitor.
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consisted of various sociodemographic, clinical or attitudinal/
psychologic variables. A backward selection approach, based on
removal when P > 0.05, was used to determine predictors of
high BMQ-Specific scores and high medication adherence. To
account for the within-subject correlations, the final model was
refitted by a random effects linear logistic model, with a patient
indicator as a random intercept.
With backward selection, the model complexity of the predic-
tion model was automatically determined from the data. A best
subset selection approach was applied to determine a simpler
prognostic model for high adherence with only four to six pre-
dictors. All variables (except type of treatment) were dichoto-
mized using the cut-off maximizing the sum of sensitivity and
specificity. The model with the highest cross-validated area
under the receiver operating characteristic curve among all can-
didate models (treatment and three dichotomous predictors for
CD and RA, treatment and five dichotomous predictors for PSO
in monotherapy) was chosen as the final prediction model.
Statistical analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA).
Results
The DACH population consists of 631 patients from Germany
(n = 298), Austria (n = 138) and Switzerland (n = 195). Demo-
graphics, disease severity and treatments are shown in Table 1
and adherence between IMIDs and medications in Fig. 1. Other
characteristics such as rural or urban locations, living arrange-
ments, children or years of education were not significantly dif-
ferent (not shown). Forgetting to take the medication (MMAS-4
question 1) was significantly more prevalent in patients receiving
conventional treatment (alone 15.9% or in combination 12.9%)
compared with patients receiving TNFi monotherapy (11.3%)
or TNFi combination therapy (6.6%).
The results for the BMQ-General (Overuse and Harm) and
BMQ-Specific (Necessity and Concerns) questionnaire are shown
in Fig. S1 (Supporting Information) by IMID and Fig. S2 (Sup-
porting Information) by treatment. BMQ-Specific results can be
translated into a Necessity–Concerns framework, which divides
patients into four attitudinal dimensions: sceptical (low neces-
sity, high concerns; 2.4%), indifferent (low necessity, low con-
cerns; 9.7%), ambivalent (high necessity, high concerns, 26.1%)
and accepting (high necessities, low concerns; 61.8%) (Fig. 2).18
The highest percentage of acceptance was found in patients with
AS, the highest percentage of those who were sceptical and indif-
ferent occurred in patients with PSO, and the highest ambiva-
lence was found in patients with RA (Fig. S3, Supporting
Information). Younger participants (≤45 years) had a tendency
to believing in a lower treatment necessity (3.1% were sceptical
and 9.7% were indifferent vs. 1.7% and 8.4% in participants
>45 years, not significant).
Single attitudinal segment had no significant influence on
adherence. By grouping the attitudinal segments into high (scep-
tical and ambivalent) vs. low (indifferent and accepting) con-
cerns, high concerns were associated with significantly less
adherence (P < 0.05), whereas grouping on necessity had no sig-
nificant influence on adherence.
The highest BIPQ score (a more threatening view towards the
illness) was reported in patients with UC and PSO, whereas less
in AS and PSA (Fig. S4, Supporting Information). Irrespective of
the treatment, the results showed that participants were aware
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Figure 1 Adherence in percentage by disease and treatment of highly and not highly adherent participants. AS, ankylosing spondylitis;
CD, Crohn’s disease; MMAS-4, Morisky Medication Adherence Scale; PSA, psoriatic arthritis; PSO, psoriasis; RA, rheumatoid arthritis,
TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis. *p < 0.05.
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that their disease is a chronic disease, that the medication is
helpful, and especially, the TNFi combo group felt like they
understand their disease (data not shown).
In a multivariable regression analysis model based on variable
selection, different factors influenced the treatment adherence of
patients directly and indirectly in a positive or negative way
(Fig. 3). Older age (>45 years, 61.3% of younger vs. 75.5% of
older patients were highly adherent; P < 0.0001), TNFi combo
(within the combination: TNFi, P < 0.0001; conventional,
P = 0.21) or TNFi mono (P = 0.0006) had a higher likelihood to
influence treatment adherence directly and positively (odds ratio
[OR] are 1.70, 12.6, 2.53 and 3.30, respectively). More than three
pretreatments (P = 0.03) or a higher rating for the overuse
(P = 0.0003) of medication (OR of 0.42 and 0.82, respectively)
had a higher likelihood of influencing treatment adherence in a
direct and negative way. Positive influence factors of treatment
concerns, which are indirect factors on adherence, were female
sex (P = 0.044), ‘Consequences’ (BIPQ-1, P = 0.0007), and ‘Ill-
ness concerns’ (BIPQ-6, P < 0.0001); negative influence factors
were ‘Control’ (BIPQ-4, P < 0.0001), ‘Symptoms’ (BIPQ-5,
P = 0.0016), and ‘Understanding’ (BIPQ-7, P < 0.0001). Positive
influence factors of necessity of treatment that were indirect fac-
tors on adherence were higher age (P = 0.0002), use of TNFi ther-
apy (mono, P = 0.015, or combination, P < 0.0001), duration
(BIPQ-2, P = 0.0004), treatment control (BIPQ-4, P < 0.0001)
and illness concerns (BIPQ-6, P = 0.0008). Necessity was nega-
tively influenced by a disease duration of >1 year (P = 0.0066;
Fig. 3, Tables S1, S2 and S3, Supporting Information).
Additionally, a risk matrix winner model was performed to
show probability of non-adherence. As the patient numbers were
limited, reasonable matrices could only be developed for RA and
CD (Figs S5 and S6, Supporting Information).
Discussion
Adherence to therapy is a central factor for controlling a disease.
Within the global ALIGN study, the DACH region was analysed
to determine general and specific beliefs towards medication and
treatment adherence in patients simultaneously in different
IMIDs.10
Treatment adherence is within previously reported ranges
(Fig. 1).2,4,7,8 By therapy, the highest adherence was seen in
the TNFi combo-TNFi rating (84.5%), vs. lowest in conven-
tional (56.0%, significant). Also, our data confirm that older
age has a positive direct effect on treatment adherence and
necessity; female sex has a positive effect on concerns, whereas
disease duration of 1 year has a negative impact on treatment
necessity and more than three previous treatments have a neg-
ative impact on treatment adherence (Table 1, Fig. 3).2,19,20
Less than one-third of the patients across all of the IMIDs were
worried about overuse and harm of their medication. Most of
the patients did not believe that they use too much medication
or consider the medication harmful (Fig. S1, Supporting Infor-
mation). Overuse has a direct negative impact on treatment
adherence (Fig. 3). In our cohort, the probability of being
treatment adherent decreases 0.8% with each 1-point increase
on the BMQ-General Overuse score (Fig. S1, Supporting Infor-
mation).
Concerns were quite low (C1, C3–5); however, the fear about
long-term effects (C2) was present in up to 64%. This indicates
that in DACH, an additional emphasis should be given to educa-
tion on long-term outcome and side-effects. Necessity was quite
high with health depending on medicine (>70%, N1) and medi-
cine protects from becoming worse (>85%, N5). Interestingly,
81% of patients in the TNFi combo group agree to strongly
agree with being very ill without medicine (N3) vs. 56% of
patients in the conventional group. Combination treatments are
normally prescribed to patients where monotherapy was insuffi-
cient, underlining their higher belief in treatment necessity.
In DACH-ALIGN, the BMQ-Specific Necessity–Concerns
framework21 shows a significant influence on adherence by com-
paring high concern (sceptical, ambivalent) vs. low concern
groups (indifferent, accepting). This indicates that a higher
emphasis on treatment concerns in different IMIDs in the
DACH region should be given (Fig. 2). These findings are in
accordance with previous studies, where lower necessity2,21–23
and higher concerns2,24–26 have a negative influence on adher-
ence. As the attitudinal segments sceptical, ambivalent, and
indifferent have a higher risk of non-adherence,21 participants in
those segments need special attention to increase treatment
necessity and to lower concerns.
Figure 2 Necessity–Concerns framework grouping patients into
four attitudinal segments by classifying results for BMQ-Speciﬁc
Necessity and Concerns into the two categories deﬁned by ‘low’
(<3.0) and ‘high’ (≥3.0) and combining the results for each patient.
Values in brackets presented depict the range for the proportion of
patients classiﬁed in each of the four attitudinal segments across
all treatment groups. BMQ, Beliefs about Medicines Questionnaire.
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In a multiple regression analysis (Fig. 3), older age
(>45 years), TNFi mono, TNFi in combination and conven-
tional therapy in combination have a positive direct effect,
whereas the belief of overuse and >3 pretreatments have a neg-
ative direct effect on adherence. Necessity and concerns both
influence treatment adherence. Positive effects on necessity
are higher age, TNFi mono, TNFi combination, BIPQ-2
(Duration), BIPQ-4 (Control) and BIPQ-6 (Illness concerns),
whereas disease duration of 1 year has a negative effect.
Female sex, BIPQ-1 (Consequences) and BIPQ-6 (Illness con-
cerns) have positive effects on concerns, whereas BIPQ-4
(Control), BIPQ-5 (Symptoms) and BIPQ-7 (Understanding)
have negative effects. It is important for HCPs in the DACH
region to be aware of these characteristics and keep them in
mind when communicating with patients. Based on our find-
ings and previous studies, we suggest a quick tool to identify
patient types (Fig. S7, Supporting Information) and a strategy
to empower certain patient types (Fig. S8, Supporting Infor-
mation).
Depending on the attitudinal patient type, the time to invest
in a good HCP–patient relationship may improve patient satis-
faction and treatment adherence.27,28 A patient-centred
approach increases patient knowledge, education, motivation,
self-efficacy, decisioning, adherence, self-care, quality of life,
treatment survival, outcome and reduces care costs.29–34 About
75% of HCPs employ a physician-directed communication35
and about 70% of patients complain about the communication
itself and not about competency.36 Patients often place higher
value on prognosis, diagnosis and causation, and the HCP over-
estimates the patients’ wishes for information about treatment.37
As shown here, long-term effects and side-effects also require
special attention (Fig. S1, Supporting Information, C2). Desired
information within a patient should be identified and kept SIM-
PLE (Simplify regimen characteristics, Impart knowledge,
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Figure 3 Multiple regression analysis showing the factors having a positive (green) or negative (red) effect on adherence either directly
(black arrow, left box) or indirectly (dotted arrow) on Necessity (lower box) or Concerns (right box). As a matter of interpretation, for each
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Modifying patient beliefs, Patient communication, Leave bias,
Evaluating adherence).38
Limitations of the study are the limited patient numbers
where possible confounding factors such as severity, treatment
response, comorbidities, possible unequal distribution, no ran-
domization or stratification could not be evaluated. Recall and
self-representational biases cannot be ruled out with the use of
self-reported questionnaires. A single, randomly chosen visit
without follow-up might lead to variable patient responses influ-
enced by different disease stages. Other reasons for treatment
non-adherence (e.g. side-effects or loss of response) were not
evaluated. Although confidential, patients may have overrated
their adherence to conform to the doctor’s expectations and to
avoid negative appraisal.
The ALIGN study was the first study to simultaneously and
extensively analyse psychosocial factors besides demographical
and treatment-related factors across six different IMIDs. In the
DACH population, high treatment concerns were significantly
associated with treatment non-adherence. Therefore, we suggest
tools to identify (Fig. S7, Supporting Information) and to
empower patient types (Fig. S8, Supporting Information). An
improvement in communication with a patient-centred
approach, focusing on patients concerns and needs, could
enhance patients’ adherence more than improvement in specific
treatments alone.
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Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Percentage of patients in each indication who
agreed or strongly agreed to the respective statements out of
the BMQ-General questionnaire containing Overuse (O1 to
O4) and Harm (H1 to H4) statements or BMQ-Specific
questionnaire containing Concerns (C1 to C5) and Necessity
(N1 to N5) statements.
Figure S2. Percentage of patients in each treatment group who
agreed or strongly agreed to the respective statements out of the
BMQ-General questionnaire containing Overuse (O1 to O4) and
Harm (H1 to H4) statements or BMQ-Specific questionnaire
containing Concerns (C1 to C5) and Necessity (N1 to N5) state-
ments.
Figure S3. Percentage of patients for each indication distributed
in the four attitudes by stacked columns.
Figure S4. BIPQ by diagnosis. The total BIPQ score was calcu-
lated as the sum of the score values of the individual items.
Figure S5. Risk matrix showing the probability of being highly
adherent (MMAS = 4) for patients with RA depending on their
age, treatment, the number of comorbidities and their answer to
BIPQ-6 (Illness concerns).
Figure S6. Risk matrix showing the probability of being highly
adherent (MMAS = 4) for patients with CD depending on their
sex, treatment, the BMQ Overuse score and the BMQ Necessity
score.
Figure S7. Factors identifying patient types by attitudinal seg-
ments.
Figure S8. Strategies for empowering a certain patient type
based on attitudinal segments.
Table S1. Parameter (variable selection) for multivariable logis-
tic regression analysis to Adherence.
Table S2. Parameter (variable selection) for multivariable logis-
tic regression analysis to Concerns.
Table S3. Parameter (variable selection) for Multivariable Logis-
tic Regression Analysis to Necessity.
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